Legal Representation
Attorney
Daniel M. Cislo,
USPTO Deadlines
Next Deadline
1153 days remaining
Section 8 Declaration Due (Supplemental Register) (Based on registration date 20230328)
Due Date
March 28, 2029
Grace Period Ends
September 28, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
47 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 28, 2023 | NRCS | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 28, 2023 | R.SR | A | REGISTERED-SUPPLEMENTAL REGISTER | Loading... |
| Feb 17, 2023 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Feb 11, 2023 | AAUA | E | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | Loading... |
| Feb 10, 2023 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| Feb 10, 2023 | CNTA | O | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | Loading... |
| Feb 10, 2023 | IUAA | P | USE AMENDMENT ACCEPTED | Loading... |
| Feb 2, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 2, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 2, 2023 | AUPC | I | AMENDMENT TO USE PROCESSING COMPLETE | Loading... |
| Jan 26, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Feb 1, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jan 26, 2023 | EAAU | I | TEAS AMENDMENT OF USE RECEIVED | Loading... |
| Jan 26, 2023 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Jan 26, 2023 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
| Jan 26, 2023 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Jan 26, 2023 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
| Sep 22, 2022 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Sep 22, 2022 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Sep 22, 2022 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jul 7, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 6, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 6, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 10, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jan 10, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 10, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 7, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 7, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 30, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 4, 2021 | AAUA | E | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | Loading... |
| May 3, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 3, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| May 3, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 3, 2021 | IUAA | P | USE AMENDMENT ACCEPTED | Loading... |
| Apr 20, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 19, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 19, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 15, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Mar 17, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 11, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 11, 2021 | EAAU | I | TEAS AMENDMENT OF USE RECEIVED | Loading... |
| Aug 1, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 1, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 1, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 29, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 12, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 29, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of COVID 19, Influenza, Autism, Alzheimer's, Parkinson's Disease, Multiple Sclerosis, Epstein-Barr Virus all of the foregoing comprised of both Zinc and Vitamin D
First Use Anywhere:
20200500
First Use in Commerce:
20200500
Additional Information
Pseudo Mark
ZINC D
Classification
International Classes
005